Omicron May Carry Greater Risk Of Reinfection Than Other Variants
A previous covid infection may not offer much immunity against omicron. Analysis of cases in South Africa indicate that this latest variant may be least three times more likely to cause a reinfection. Other news on the mutated virus is reported as scientists race to study it.
The Washington Post:
Omicron Covid Variant Has Higher Risk Of Reinfection Than Delta, South Africa Researchers Say
Scientists in South Africa say omicron is at least three times more likely to cause reinfection than previous variants such as beta and delta, according to a preliminary study published Thursday. Statistical analysis of some 2.8 million positive coronavirus samples in South Africa, 35,670 of which were suspected to be reinfections, led researchers to conclude that the omicron mutation has a “substantial ability to evade immunity from prior infection.” (Cheng, 12/3)
The New York Times:
Omicron Variant Reinfects People Who Have Had The Coronavirus
A past coronavirus infection appears to give little immunity to the new Omicron variant rippling across the globe, South African scientists warned on Thursday, potentially tearing away one layer of defense that humanity has won slowly and at immense cost. Just a week after its existence was revealed to the world, the heavily mutated variant, which scientists fear could be the most contagious one yet, is already by far the dominant form of the virus in South Africa and spreading fast, according to officials there. Top European disease experts said Thursday that it could be the dominant form in Europe within a few months. (Chutel and Pérez-Peña, 12/2)
Meanwhile, the World Health Organization addresses omicron —
Bloomberg:
Key Omicron Findings May Be Known In Days, WHO Scientist Says
Some 450 researchers around the world have begun work to isolate the highly mutated variant from patient specimens, grow it in the lab, verify its genomic sequence, and establish methods to test it in blood-plasma samples, said Ana-Maria Henao-Restrepo, who co-leads the WHO’s research and development blueprint for vaccines and innovations during outbreaks and pandemics. “They hope that this will happen within days, but I think we should not put pressure that it should happen within three days -- we should say it will happen within the next two weeks,” she said in a Zoom interview from Geneva Wednesday. (Gale, 12/3)
Axios:
WHO: Delta Health Measures Help Fight Omicron
Health measures taken to combat COVID-19 before the emergence of Omicron would also help against the new variant of concern, World Health Organization officials said Friday. Takeshi Kasai, WHO regional director for the Western Pacific, said during a virtual briefing broadcast from Manila, Philippines, that border controls imposed by the U.S. and other nations can "buy time" to deal with the variant, but warned "every country and every community must prepare for new surges in cases." (Falconer, 12/3)
AP:
WHO Says Measures Against Delta Work For Omicron Variant Too
World Health Organization officials in the Western Pacific say border closures adopted by some countries may buy time to deal with the omicron coronavirus variant, but measures put in place and experience gained in dealing with the delta variant should remain the foundation for fighting the pandemic. While a few regional countries are facing surges, COVID-19 cases and deaths in many others have decreased and plateaued, WHO Regional Director for the Western Pacific Dr. Takeshi Kasai told reporters Friday in a virtual news conference broadcast from Manila, Philippines. (Gomez, 12/3)
In other omicron developments —
Reuters:
Roche Develops New Research Test Kits For Omicron Variant
"We are able to offer a test that can specifically identify the novel B.1.1.529 Omicron SARS-CoV-2 variant to help better understand its spread and behaviour," Thomas Schinecker, head of Roche Diagnostics, said in a statement. While the WHO has said widely available tests can detect individuals infected with any variant, most PCR tests cannot distinguish between Omicron and Delta, the dominant and most infectious version of the virus. (Hughes Neghaiwi, 12/3)
The New York Times:
The E.U.’s Health Agency Says Omicron Could Be Dominant In Europe By Spring
The Omicron variant could become the dominant version of the coronavirus in Europe in the next few months, the European Center for Disease Prevention and Control said on Thursday, as the continent faced a surge of new infections and deaths that has prompted many governments to tighten restrictions. The European Union’s infectious disease agency acknowledged in a report that there were “a number of uncertainties” related to the Omicron variant, including how transmissible it is, how likely it is to cause severe symptoms and how effective existing vaccines are against it. But preliminary data already suggests that Omicron, which carries a large number of mutations compared with the original virus, has a “substantial advantage” over previous versions of the virus, the agency said. (Pronczuk, Kitsantonis, Minder, Kumar and Specia, 12/2)
Stat:
How To Interpret The Coming Data On Omicron And Covid Immunity
At some point in the next few weeks, scientists will start releasing data from lab experiments that can help illuminate just how much of a threat the Omicron variant poses to existing Covid-19 vaccines and our immunity. But there won’t be one clear conclusion reported at one time. The results will come out in drips — one preprint study posted here, one company press release there. Together, these lab studies, combined with the clinical outcomes of patients infected with the variant, will help experts form a broader understanding of Omicron’s impact — and whether, if it takes off globally, we might need to adapt our vaccines. (Joseph, 12/3)
NPR:
Sending the Right Message About the Omicron Variant Is Tricky
With the first case of omicron confirmed in California and more cases expected across the U.S., public health officials who know the difference between good and bad crisis communication say they can't afford to be quiet and wait until scientists know how risky the new variant is before they speak out. "We don't want to just be silent on the matter, because then that can cause fear and then that can allow for misinformation to creep in," says Elya Franciscus, the epidemiology operations manager for COVID-19 in Harris County, Texas. (Simmons-Duffin, 12/2)
